JW Lifescience Corporation (KRX:234080)
South Korea · Delayed Price · Currency is KRW 11,030
-110 (-0.99%)
Last updated: Aug 3, 2026, 3:00 PM KST
JW Lifescience Ratios and Metrics
Market cap in millions KRW. Fiscal year is January - December.
Millions KRW. Fiscal year is Jan - Dec.
Total Valuation
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
| 172,962 | 198,977 | 168,472 | 199,286 | 188,137 | 214,461 | |
Market Cap Growth | -8.07% | 18.11% | -15.46% | 5.93% | -12.27% | -34.73% |
Enterprise Value | 203,012 | 222,030 | 157,490 | 227,270 | 221,603 | 261,011 |
Last Close Price | 11170.00 | 12315.80 | 10427.69 | 11792.53 | 10711.11 | 11730.97 |
Price Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
PE Ratio | 5.92 | 6.96 | 3.83 | 7.08 | 12.58 | 16.61 |
Forward PE | - | 9.92 | 9.92 | 9.92 | 9.92 | 9.92 |
PS Ratio | 0.68 | 0.77 | 0.76 | 0.96 | 1.00 | 1.26 |
PB Ratio | 0.79 | 0.90 | 0.84 | 1.25 | 1.34 | 1.63 |
P/TBV Ratio | 1.22 | 1.39 | 1.37 | 1.28 | 1.38 | 1.69 |
P/FCF Ratio | 5.00 | 7.11 | 4.17 | 6.77 | 31.10 | 19.17 |
P/OCF Ratio | 3.65 | 4.91 | 3.32 | 5.30 | 13.32 | 7.11 |
PEG Ratio | - | 1.75 | 1.75 | 1.75 | 1.75 | 1.75 |
EV Ratios
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
EV/Sales Ratio | 0.80 | 0.86 | 0.71 | 1.10 | 1.17 | 1.54 |
EV/EBITDA Ratio | 3.91 | 4.32 | 3.05 | 4.90 | 5.27 | 6.27 |
EV/EBIT Ratio | 6.08 | 6.68 | 4.39 | 7.36 | 8.18 | 9.19 |
EV/FCF Ratio | 5.87 | 7.94 | 3.90 | 7.73 | 36.63 | 23.33 |
Financial Efficiency
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Debt / Equity Ratio | 0.19 | 0.23 | 0.35 | 0.29 | 0.48 | 0.35 |
Debt / EBITDA Ratio | 0.81 | 0.98 | 1.34 | 1.00 | 1.60 | 1.12 |
Debt / FCF Ratio | 1.22 | 1.81 | 1.72 | 1.57 | 11.11 | 4.16 |
Net Debt / Equity Ratio | 0.14 | 0.18 | 0.30 | 0.11 | 0.27 | 0.32 |
Net Debt / EBITDA Ratio | 0.58 | 0.78 | 1.16 | 0.39 | 0.91 | 0.99 |
Net Debt / FCF Ratio | 0.87 | 1.43 | 1.48 | 0.61 | 6.34 | 3.70 |
Asset Turnover | 0.79 | 0.80 | 0.77 | 0.81 | 0.80 | 0.78 |
Inventory Turnover | 5.65 | 5.53 | 5.61 | 6.80 | 6.54 | 6.38 |
Quick Ratio | 0.68 | 0.66 | 0.87 | 0.89 | 1.03 | 0.45 |
Current Ratio | 1.09 | 1.05 | 1.32 | 1.14 | 1.31 | 0.77 |
Return on Equity (ROE) | 13.98% | 13.59% | 24.45% | 18.78% | 11.01% | 9.78% |
Return on Assets (ROA) | 6.53% | 6.46% | 7.71% | 7.58% | 7.17% | 8.19% |
Return on Invested Capital (ROIC) | 11.94% | 11.51% | 12.22% | 14.48% | 11.09% | 11.83% |
Return on Capital Employed (ROCE) | 14.30% | 14.20% | 14.60% | 19.10% | 15.70% | 21.00% |
Yields
Fiscal Year | Current | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 |
|---|---|---|---|---|---|---|
Period Ending | Aug '26 Aug 3, 2026 | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 |
Earnings Yield | 16.87% | 14.38% | 26.11% | 14.12% | 7.95% | 6.02% |
FCF Yield | 20.01% | 14.06% | 23.97% | 14.76% | 3.21% | 5.22% |
Dividend Yield | 5.06% | - | - | 4.24% | 4.67% | 4.26% |
Payout Ratio | 26.53% | 27.07% | 17.60% | 27.51% | 51.75% | 61.31% |
Buyback Yield / Dilution | 0.04% | -0.01% | 0.01% | - | 0.61% | 1.61% |
Total Shareholder Return | 5.11% | -0.01% | 0.01% | 4.24% | 5.28% | 5.87% |